Figure 1.
Characterization of the patients with UC.
Patients with UC were treated with the ATM therapy (n = 12) or placebo (n = 8) for 2 weeks. (A) The symptom score (upper panel), endoscopic score (middle panel), and histological score (lower panel) at 3 months after the ATM treatment or placebo were compared with the trial start. (B) Inflammatory markers such as the erythrocyte sedimentation rate (upper panel), white blood cell count (middle panel), and C-reactive protein (CRP) (lower panel) at 3 months after the ATM treatment or placebo were compared with the trial start. The results are expressed as the mean ± SD. ***P<0.001; **P<0.01; *P<0.05.
Table 1.
Clinical characterization of patients with ulcerative colitis in antibiotics and placebo groups.
Table 2.
Symptom score, endoscopic finding score, histological score, and inflammatory markers in antibiotics and placebo groups.
Figure 2.
Representative T-RFLP patterns of 16S rDNAs from mucosal bacteria.
(A) There were no characteristic peak patterns in the ATM treatment groups. At 3 months after treatment completion, the peak heights of the restriction enzyme HhaI were changed in the ATM therapy group (A) but not changed in the placebo group (B).
Figure 3.
Dendrogram of T-RFLP profiles before and after the ATM therapy.
(A) The similarity dendrogram was constructed using a binary coefficient dendrogram (Dice-UPGMA). The numbers indicate the subject code number in the ATM and placebo groups. A; after therapy, B; before therapy. (B) Similarity values from the dendrogram at trial start and again at 3 months after treatment completion (ATM or placebo) were analyzed. The results are expressed as the mean ± SD. *P<0.05.